CERo Therapeutics Holdings (CERo Therapeutics Holdings) Cash-to-Debt : 2.26 (As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CERo Therapeutics Holdings's cash to debt ratio for the quarter that ended in Dec. 2022 was 2.26.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, CERo Therapeutics Holdings could pay off its debt using the cash in hand for the quarter that ended in Dec. 2022.

The historical rank and industry rank for CERo Therapeutics Holdings's Cash-to-Debt or its related term are showing as below:

CERO' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.26 Med: 3.8 Max: 5.34
Current: 2.26

During the past 2 years, CERo Therapeutics Holdings's highest Cash to Debt Ratio was 5.34. The lowest was 2.26. And the median was 3.80.

CERO's Cash-to-Debt is ranked worse than
65.8% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs CERO: 2.26

CERo Therapeutics Holdings Cash-to-Debt Historical Data

The historical data trend for CERo Therapeutics Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CERo Therapeutics Holdings Cash-to-Debt Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Cash-to-Debt

5.34

2.26

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Cash-to-Debt	5.34	2.26

Competitive Comparison of CERo Therapeutics Holdings's Cash-to-Debt

For the Biotechnology subindustry, CERo Therapeutics Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CERo Therapeutics Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Cash-to-Debt falls into.

CERo Therapeutics Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

CERo Therapeutics Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.82	/	(0.672	+	2.345)
	=	2.26

CERo Therapeutics Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.82	/	(0.672	+	2.345)
	=	2.26

CERo Therapeutics Holdings (NAS:CERO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

CERo Therapeutics Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024